Cybin reports third quarter fiscal year 2025 financial results and recent business highlights

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe canada ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its third quarter ended december 31, 2024, and recent business highlights. “as we advance our lead clinical programs, cyb003 and cyb004, our focus in 2025 remains on continued.
CYBN Ratings Summary
CYBN Quant Ranking